Transfersomes: Recent Advances, Mechanisms, Exhaustive Applications, Clinical Trials, and Patents.

A feasible nano transdermal delivery system generally intends to have specific ideal and distinct characteristics primarily for safety, clinical efficacy, and boosted therapeutic index. The delivery of drugs, particularly macromolecules, across the skin is one of the most strenuous obstacles in front of pharmaceutical scientists. Technology advancement has provided some opportunities to overcome this difficulty by utilising microneedle arrays, ablation, laser methods etc.

Role of Nanoformulations in the Treatment of Lung Cancer.

Lung cancer is the second deadliest disease in the world. A major portion of deaths related to cancer are due to lung cancer in both males and females. Interestingly, unbelievable advances have occurred in recent years through the use of nanotechnology and development in both the diagnosis and treatment of lung cancer.

Nano-based therapeutics for Rheumatoid arthritis: Recent patents and development.

Rheumatoid arthritis (RA) is a chronic, systemic autoimmune disease marked by inflammation of synovium and generation of autoantibodies. Bone and cartilage are frequently damaged along with weakening of tendons and ligaments resulting in disability. An effective RA treatment needs a multi-disciplinary approach which relies upon pathophysiology that is still partially understood.

An Overview of the Recent Developments and Patents in the Field of Pharmaceutical Nanotechnology.

Background: Compared to traditional dosage methods, the Novel Drug Delivery Systems (NDDS) provide various advantages. In the last few years, the interest shifted to works focused on the novel drug delivery methods for small and large molecular drug carriers utilizing particulate drug delivery systems as well. It is evident from the last decade as observed in increased number of patents in this field that the technology has evolved tremendously.

Nanoemulsion: A Novel Drug Delivery Approach for Enhancement of Bioavailability.

Background: Poor bioavailability and solubility of drugs in aqueous phase are the most important problems of newly developed chemical entities that can be improved by nanoemulsion.

Objectives: BCS class II and IV which are poorly soluble in water demonstrate various problems in conventional dosage forms. For the improvement of solubility, bioavailability and getting the best therapeutic effect of poorly soluble drugs nanoemulsion is the best solution.